Abstract: OBJECTIVE To explore the research hotspots and research trends in the field of inhaled triple drugs therapy for chronic obstructive pulmonary disease(COPD) since 2000 by conducting a bibliometric analysis of triple therapy drugs. METHODS Based on CiteSpace and VOSviewer software, the core database of Web of Science was searched, and the annual publication volume, authors, institutions, journals and keywords of the filtered literature were visually analyzed, and the clustering of institutions and the timeline of keywords were analyzed. Discuss with the highlighted year. RESULTS From 2000 to 2022, the number of publications related to COPD inhaled triple therapy drugs was 403, showing an overall increasing trend, mainly in the United States, the United Kingdom, Italy, Germany, Canada and other countries; the top 5 authors with the number of published papers were SINGH D, LIPSON D, MARTINEZ F, DORINSKY P and ISMAILA A, which were consistent with GlaxoSmithKline, AstraZeneca, The University of Manchester, University of Pennsylvania and McMaster University, the top 5 research institutes with the largest number of publications. Related clinical trials, drug inhaler technology and types were the hot spots and key directions of research in the field of inhaled triple drugs therapy for COPD; single-inhaler triple therapy, multi-inhaler triple therapy, patient survival rate, and treatment effectiveness were the frontiers of triple therapy research content. CONCLUSION Since 2014, inhaled triple-drug therapy for COPD has received more and more attention. The pathophysiology of the disease, clinical trials and main outcome indicators of triple-drug therapy, and inhaler technology are the research hotspots in this field, and single-inhaler triple therapy is the frontier research direction in this field. The depth and international influence of Chinese related research needs to be further improved.